SOENIA® is a company that addresses challenges faced by refractory epilepsy patients. The SOENIA® UltimateEEG™ Subscalp Electrode aims for continuous, high-precision monitoring and therapeutic neuromodulation, providing a comprehensive approach to epilepsy management. The innovative proprietary electrodes are a breakthrough in multichannel recording and stimulation with the aim to treat refractory epilepsy under local anesthesia with a small incision. 

SOENIA® will collaborate with eemagine in two ways to address the monitoring and therapeutic needs of refractory epilepsy patients. Firstly, the collaboration aims to measure subscalp EEG as a temporary recording as an intermediate monitoring device to record seizures. The longer-term aim is to help neurologists identify patients suitable for therapeutic implants such as difficult-to-detect seizures that would benefit from temporary recording in the patient's natural environment instead of an EEG laboratory.

Secondly, SOENIA® will investigate neuromodulation patterns suitable for subdermal stimulation from the external eemagine RIO device targeting focal refractory epilepsy. These patterns will be developed for the SOENIA® UltimateEEG™ Subdermal Electrode to accommodate the RIO RX300’s three stimulation channels plus three recording channels. The long-term goal is to identify a neurostimulation strategy that benefits patients. 

By combining these two approaches, we will be able to address a substantial unmet need for an advanced, patient-friendly solution that offers continuous monitoring and effective therapeutic intervention for refractory epilepsy.